New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
07:31 EDTXLRN, GERN, ARGS, THLD, MDCO, EGRX, ANAC, SGMO, INSY, DSCOPiper Jaffray to hold a symposium
Catalyst Symposium to be held in Boston on July 8.
News For ANAC;ARGS;DSCO;EGRX;GERN;INSY;MDCO;XLRN;SGMO;THLD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 31, 2015
09:11 EDTMDCOEuropean Society of Cardiology
Subscribe for More Information
09:01 EDTMDCOThe Medicines Co. price target raised to $53 from $40 at Leerink
Subscribe for More Information
08:10 EDTMDCOThe Medicines Co. price target raised to $45 from $34 at JPMorgan
Subscribe for More Information
07:45 EDTMDCORegeneron should be bought on any pullbacks, says RBC Capital
Subscribe for More Information
07:43 EDTMDCOThe Medicines Co. price target raised to $42 from $32 at Citi
Subscribe for More Information
07:38 EDTMDCOThe Medicines Co. price target raised to $46 from $39 at RBC Capital
Subscribe for More Information
07:31 EDTMDCOThe Medicines Company names Fred Eshelman non-executive chairman
Subscribe for More Information
August 30, 2015
15:50 EDTMDCOAlnylam, The Medicines Co. say ALN-PCSsc reduces LDL cholesterol as much as 83%
Subscribe for More Information
August 28, 2015
17:23 EDTGERNGeron files $250M mixed securities shelf
12:59 EDTMDCOFly Watch: Medicines Co., Alnylam rise ahead of cholesterol study presentation
Subscribe for More Information
10:13 EDTMDCOHigh option volume stocks
Subscribe for More Information
10:02 EDTMDCOOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ADP (ADP) upgraded to Outperform from Market Perform at William Blair... ASML (ASML) upgraded to Buy from Hold at Berenberg... Abercrombie & Fitch (ANF) upgraded on Hollister fundamentals at RBC Capital... Akamai (AKAM) upgraded to Outperform from Market Perform at JMP Securities... Ares Capital (ARCC) upgraded to Outperform from Market Perform at Raymond James... Banco Santander (SAN) upgraded on valuation at Deutsche Bank... CIBC (CM) upgraded to Neutral from Underperform at Credit Suisse... Canon (CAJ) upgraded to Hold from Sell at Deutsche Bank... Citi (C) upgraded to Buy from Neutral at Guggenheim... Ctrip.com (CTRP) upgraded to Buy from Hold at Stifel... El Pollo Loco (LOCO) upgraded at Stifel... Genomic Health (GHDX) upgraded to Market Perform from Underperform at Raymond James... Golar LNG (GLNG) upgraded on valuation, upcoming project completion at Stifel... Habit Restaurants (HABT) upgraded to Buy from Hold at Stifel... Helmerich & Payne (HP) upgraded to Overweight from Equal Weight at Stephens... Himax (HIMX) upgraded to Outperform from Neutral at Credit Suisse... Huntington Bancshares (HBAN) upgraded to Buy from Neutral at Guggenheim... InterContinental (IHG) upgraded to Outperform from Neutral at Credit Suisse... Knight Transportation (KNX) upgraded to Strong Buy on valuation at Raymond James... LogMeln (LOGM) upgraded to Overweight from Sector Weight at Pacific Crest... Patterson Companies (PDCO) upgraded to Overweight from Neutral at Piper Jaffray... Qunar (QUNR) upgraded on valuation, positive catalysts at Stifel... Regions Financial (RF) upgraded to Buy from Neutral at Guggenheim... Ryder (R) upgraded to Strong Buy from Outperform at Raymond James... SVB Financial (SIVB) upgraded to Buy from Neutral at DA Davidson... Seagate (STX) upgraded to Buy from Hold at Cross Research... Sinopec (SNP) upgraded to Neutral from Sell at Citi... Summit Hotel Properties (INN) upgraded to Outperform at Baird... Texas Capital (TCBI) upgraded to Buy from Neutral at DA Davidson... The Medicines Co. (MDCO) upgraded to Buy from Hold at Jefferies... U.S. Bancorp (USB) upgraded to Buy from Neutral at Guggenheim... Weatherford (WFT) upgraded to Overweight from Equal Weight at Stephens.
07:12 EDTEGRXWilliam Blair names 21 stocks best positioned for volatile markets
Subscribe for More Information
06:35 EDTMDCOThe Medicines Co. upgraded to Buy from Hold at Jefferies
Jefferies upgraded The Medicines Co. to Buy and increased its price target to $43 from $29. The firm said company has multiple data readouts for pipeline assets over the next 12-18 months starting with PI data from ALN-PCSsc in patients with elevated LDL on Sunday morning. Jefferies also highlighted the ongoing TANGO 1 trial comparing Carbavance to piperacillin-tazobactam in 850 patients with complicated urinary tract infection with data expected in mid-2016 that should also support its thesis.
August 27, 2015
17:08 EDTINSYInsys Therapeutics receives purported service of notice of three IPR petitions
On August 26, Insys Therapeutics received purported service of notice of three inter partes review petitions filed by a hedge fund with the U.S. Patent and Trademark Office, challenging three of the four Orange Book-listed patents covering Subsys. The company intends to oppose the request to institute the IPR and, if any of the three petitions are granted, the company intends to defend the validity of each patent challenged in each IPR.
11:15 EDTANACAnacor management to meet with Jefferies
Subscribe for More Information
07:19 EDTTHLDThreshold Pharmaceuticals initiates Phase 2 trial of tarloxotinib bromide
Subscribe for More Information
August 24, 2015
11:43 EDTMDCOThe Medicines Co. and Alnylam Pharmaceuticals hold a joint conference call
Subscribe for More Information
08:35 EDTARGSArgos Therapeutics awarded patent for immunotherapy for treatment of HIV
Subscribe for More Information
August 21, 2015
08:10 EDTANACAnacor: Coalition seeks to invalidate patents for Kerydin
In a regulatory filing, Anacor said that on August 20, a hedge fund -- acting with affiliated parties and proceeding under the name of the Coalition for Affordable Drugs X LLC -- filed petitions with the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office seeking to institute inter partes review proceedings to invalidate Anacor Pharmaceuticals, Inc.'s Orange Book-listed U.S. Patents Nos. 7,582,621 and 7,767,657 covering KERYDIN topical solution, 5%.If one or more of CFAD's IPR petitions are accepted by the PTAB, the Company will have three months to file its preliminary responses. Upon receipt of the Company's preliminary responses, the PTAB will have another three months in which to institute or deny the IPR proceedings. If the IPR proceedings are instituted by the PTAB, CFAD will have an opportunity to challenge the validity of some or all of the claims in the Kerydin Orange Book Patents before the PTAB. The Company is currently reviewing CFAD's IPR petitions and intends to vigorously oppose the institution of the IPR proceedings and, if the IPR proceedings are instituted, to vigorously defend the Kerydin Orange Book Patents.
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use